US2012101052A9PendingUtilityA9
15-thia steroid compounds and compositions
Est. expiryNov 24, 2018(expired)· nominal 20-yr term from priority
Inventors:James M. Frincke
A61P 7/00A61P 9/00A61P 31/12A61P 19/00A61P 1/04A61K 47/34A61K 47/44A61K 31/343A61K 31/57A61P 17/06A61K 9/0019A61P 17/00
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
Claims
exact text as granted — not AI-modified1 . A compound having the structure
wherein the dotted line is an optional double bond;
R 1 , R 2 , and R 4 independently are —OH, an ester or an ether;
R 3 is —OH, an ester, an ether or halogen;
R 5 is —CH 3 or —CH 2 OH;
R 6 is —H or —CH 3 ;
and R 7 is —S—.
2 . The compound of claim 1 wherein R 1 , R 2 and R 4 are —OH or an ester and R 3 is —OH, an ester or —Br.
3 . The compound of claim 2 wherein R 5 is —CH 3 .
4 . The compound of claim 1 wherein the compound has the formula
5 . The compound of claim 4 wherein R 1 , R 2 and R 4 are —OH or an ester and R 3 is —OH, an ester or —Br.
6 . The compound of claim 5 wherein R 5 and R 6 are —CH 3 .
7 . The compound of claim 1 wherein the compound has the structure
8 . The compound of claim 1 wherein the compound has the formula
9 . The compound of claim 8 wherein R 1 , R 2 and R 4 are —OH or an ester and R 3 is —OH, an ester or —Br.
10 . The compound of claim 9 wherein R 5 and R 6 are —CH 3 .
11 . The compound of claim 10 wherein the compound has the structure
12 . The compound of claim 11 wherein the compound has the structure
13 . A pharmaceutical formulation comprising one or more excipients and a compound having the structure
wherein the dotted line is an optional double bond;
R 1 , R 2 , and R 4 independently are —OH, an ester or an ether;
R 3 is —OH, an ester, an ether or halogen;
R 5 is —CH 3 or —CH 2 OH;
R 6 is —H or —CH 3 ;
and R 7 is —S—.
14 . The pharmaceutical formulation of claim 13 wherein R 1 , R 2 and R 4 are —OH or an ester, R 3 is —OH, an ester or —Br and R 5 and R 6 are —CH 3 .
15 . The pharmaceutical formulation of claim 13 wherein the pharmaceutical formulation has the formula
16 . The pharmaceutical formulation of claim 16 wherein R 1 , R 2 and R 4 are —OH or an ester and R 5 and R 6 are —CH 3 .
17 . The pharmaceutical formulation of claim 13 wherein the pharmaceutical formulation has the structure
18 . The pharmaceutical formulation of claim 13 wherein the compound has the structure
19 . The pharmaceutical formulation of claim 18 wherein the compound has the structureCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.